Dr. Chari on the FDA Approval of Belantamab Mafodotin in R/R Multiple Myeloma

Video

In Partnership With:

Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in ​relapsed/refractory multiple myeloma. 

Ajai Chari, MD, a professor of medicine, a hematologist, and an oncologist at Mount Sinai Hospital, discusses the approval of belantamab mafodotin-blmf (Blenrep) in ​relapsed/refractory multiple myeloma. 

Belantamab mafodotin in an antibody-drug conjugate (ADC) that is composed of a toxin attached to a cytotoxic payload, says Chari. Moreover, the agent targets BCMA, and the conjugate is monomethyl auristatin F. 

Notably, ​the agent was FDA approved on August 5, 2020 for ​the treatment of adult patients with relapsed/refractory multiple myeloma who have received 4 prior lines of therapy, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug. 

​The approval was based on findings from the phase 2 DREAMM-2 trial, ​which demonstrated an overall response rate of 31% in patients who received the recommended 2.5 mg/kg dose of belantamab mafodotin and 34% in patients who received the 3.4 mg/kg dose.

Related Videos
Ariel Grajales-Cruz, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic